Lupin Limited — Updates, 16-07-2025: Press Release

Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States. This product is bioequivalent to Lotemax® and targets steroid-responsive inflammatory eye conditions, including post-operative inflammation. The reference drug Lotemax® had estimated annual sales of USD 55 million in the U.S. This strategic launch expands Lupin's ophthalmic portfolio, positioning it to capture a share of this significant market and potentially enhance future revenue streams.